Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20233632 | 0.83 | PDE4D (0.38) | PDE4DTSHRNAAAEPHX2LIPG | |
| SCHEMBL16533210 | 0.83 | CTSL (0.50) | TSHRNAAAEPHX2CTSLCTSB | |
| SCHEMBL426503 | 0.83 | CTSL (0.50) | TSHRNAAAEPHX2CTSLCTSB | |
| SCHEMBL989536 | 0.83 | CTSL (0.50) | TSHRNAAAEPHX2CTSLCTSB | |
| SCHEMBL21811816 | 0.81 | SMN1; SMN2 (0.43) | PDE4DTSHREPHX2LIPGHTT | |
| SCHEMBL23868167 | 0.81 | TSHR (0.52) | TSHRNAAALIPGLTA4HLMNA | |
| SCHEMBL20129162 | 0.80 | TSHR (0.47) | TSHRNAAAEPHX2LIPGLTA4H | |
| SCHEMBL20129240 | 0.80 | TSHR (0.47) | TSHRNAAAEPHX2LIPGLTA4H | |
| SCHEMBL24761916 | 0.78 | TSHR (0.41) | PDE4DTSHRNAAALIPGLTA4H | |
| SCHEMBL21456425 | 0.78 | TSHR (0.48) | TSHRNAAALIPGLTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | PDE4D 4156/4885TSHR 3954/4885NAAA 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.